ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ezetimibe

Also written as “ezetimibe”, “ezetimibe (+) simvastatin” and “MK0653, ezetimibe”.

Its studies are mostly in Hypercholesterolemia · Hypertension · Hyperlipidemias · Lipid Metabolism, Inborn Errors · Atherosclerosis, led by 16 companies.

Drug pageEzetimibe: every studyMany companies study it; this page follows only the 97 they lead. All 208 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 7, 200597 company-led studies, 3 open or runningNext primary completion: Jun 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organonits history only710 open or runningphase 4since Sep 7, 2005Sep 23, 2004none ahead
Daiichi Sankyoits history only61 open or runningphase 4since Sep 9, 2005Sep 9, 2005Jun 1, 2028phase 3 · NCT07474649
Yuhan40 open or runningphase 4since Jul 12, 2017Jul 12, 2017none ahead
IlDong Pharmaceuticalits history only20 open or runningphase 3since Sep 25, 2014Sep 25, 2014none ahead
JW Pharmaceuticalits history only21 open or runningphase 4since Feb 18, 2026Oct 6, 2020none ahead
Novartisits history only20 open or runningphase 4since Oct 10, 2006Sep 12, 2005none ahead
Celltrionits history only10 open or runningphase 3since Apr 27, 2026Apr 27, 2026none ahead
Daewon Pharmaceuticalits history only10 open or runningphase 3since Jul 24, 2023Jul 24, 2023none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since Mar 22, 2012Mar 22, 2012none ahead
Hanlim Pharm.its history only10 open or runningphase 3since Dec 2, 2020Dec 2, 2020none ahead

Also a collaborator on its studies: Pharma Medica Research, Regeneron Pharmaceuticals, Merck Frosst Canada, Linical Korea and Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Yuhan only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 12, 2017First study: phase 4 study in Diabetes MellitusFirst studyNCT03217409 · 85 enrolled · Korea, Republic of
  2. Mar 11, 2019Phase 3 study in HypercholesterolemiaNCT03872232 · 180 enrolled · Korea, Republic of
  3. Aug 8, 2019Phase 4 study in Acute Coronary SyndromeNCT04056169 · 50 enrolled · Korea, Republic of
  4. Nov 7, 2019Phase 3 study in HypercholesterolemiaNCT04158076 · 131 enrolled · Korea, Republic of

TargetBeta

NPC1L1 →read by rule
“Niemann-Pick C1-like protein 1 inhibitor”ChEMBL 37, by rule

Studies

All 4 Yuhan leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04158076Hypercholesterolemia · Korea, Republic of3CompletedJan 14, 2021131
NCT04056169Acute Coronary Syndrome · Korea, Republic of4CompletedJul 23, 201950
NCT03872232Hypercholesterolemia · Korea, Republic of3CompletedAug 12, 2020180
NCT03217409Diabetes Mellitus · Korea, Republic of4CompletedApr 3, 201985

How it is read

Names in the registry

  • “Ezetimibe”, 31 entries
  • “ezetimibe”, 11 entries
  • “ezetimibe (+) simvastatin”, 10 entries
  • “MK0653, ezetimibe”, 7 entries
  • “CKD-828, D097, D337”, 6 entries

Codes read as this program: MK0653.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.